Exelixis | EXEL - Debt



Exelixis reported $179.84M in Debt for its fiscal quarter ending in June of 2025.


Debt Change Date
Acadia Pharmaceuticals USD 56.29M 56.29M Jun/2025
Agios Pharmaceuticals USD 48.76M 48.76M Jun/2025
Amgen USD 56.2B 1.18B Jun/2025
AstraZeneca USD 32.84B 1.19B Jun/2025
Bayer EUR 39.39B 1.31B Mar/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Cytokinetics USD 658.13M 1.01M Mar/2025
Eisai JPY 187.52B 31.58B Mar/2025
Eli Lilly USD 39.9B 1.39B Jun/2025
Exelixis USD 179.84M 179.84M Jun/2025
Genmab DKK 148M 5M Jun/2025
Glaxosmithkline GBP 17.35B 368M Jun/2025
Incyte USD 42.41M 5.29M Jun/2025
Ionis Pharmaceuticals USD 1.42B 169.27M Jun/2025
MacroGenics USD 37.25M 37.25M Jun/2025
Merck USD 34.84B 2.27B Mar/2025
Moderna USD 741M 4M Jun/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Novartis USD 31.27B 12M Mar/2025
Pfizer USD 60.93B 1.18B Jun/2025
Sanofi 22.28B 4.38B Jun/2025
Takeda JPY 4.51T 9.32B Jun/2025
Ultragenyx Pharmaceutical USD 36.3M 1.98M Jun/2025
Xencor USD 67.93M 86.45M Jun/2025